Sunway Biotech Co., Ltd. · TPEX:1271
Sunway Biotech — Investor Presentation (November 2016)
18 slides from Sunway Biotech's investor presentation, Nov 18, 2016
Slide 1: Why do supplement users take supplements?
WHY DO SUPPLEMENT USERS TAKE SUPPLEMENTS? 24% healthy aging 17% the isk of Biotech Co., LTD.
Slide 2: All these concerns come from...
All these concerns come from .....: Systolic BP: 120~139 mmHg [ ) Diastolic BP: 80~89 mmHg 1 OUT 3 OF Borderline High Cholesterol Prediabetes Prehypertension TC: 2240 mg/dL FBG: 2126 mg/dL Systolic BP: 2140 mmHg Diastolic BP: 290 mmHg W = High . : Cholesterol ~ Diabetes Hypertension High risk Subhea
Slide 3: Top 10 causes of death in high income countries
Ischaemic heart disease Stroke Alzheimer’s disease, dementias Ton 10 causes of death in high income countries Iliness High Risk ent a0 " ea = chronic ae can increase eueks 7 Homontta is the most common type of dementia 52 ~~ million Americans in 2016 Sources: Alzheimer's Association 2016 and World H
Slide 4: That is why you need ANKASCIN 568+
That is why you neod aa, ANKASGIN’ 568+ rar, Active Compounds : Monascin Ankaflavin e The only red yeast rice ingredient with NO statins, backed by the FDA-approved New Dietary Ingredient (NDI) status e Manufactured with the patented strain and automated solid- state fermentation technology (Monascu
Slide 5: FDA-approved NDI, trials, publications, patents
we y.3 568-R FDA, 20, Graf ) & NDI 2 ey FDA-approved Scientific Global Trials New Dietary Ingredient Publications oath Ree Patents Non-GMO 1S022000 HACCP No Major Food Allergens
Slide 6: Reasons why you should choose ANKASCIN 568-R
reasons why you should choose ANKASGIN®568-R Lipids/Sugar/Pressure 6 NO stannaisks YN site tect FDA "NDI ob de Better Better than than other Fish Oil Red Yeast Rice
Slide 7: Animal Testing and Clinical Trials
Vi Animal Testing Vi Clinical Trials Blood Lipids Blood Sugar Blood Pressure Memory & Cognitive Health
Slide 8: Manages blood lipids (animal testing)
568-R manages blood lipids Se As = ois <—>{-- Animal Testing if one | . Lipid Aashienelegigmage = oa p in heart aorta , ¥ | Z Normal Diet High Cholesterol Monacolin K Diet Compared with Monacolin K (lovastatin), Monascin and Ankaflavin had better effects on anti-atherosclerosis
Slide 9: Clinical trial: cholesterol and LDL-C
mg/dL <—-e Clinical Trial : Cholesterol LDL-C 240 170 bh () oso 11.1% 100 -20.4% 150 220 _, 140 3 210 2 130 200 120 110 190 100 180 90 Week 0 Week 4 Week 8 Week 12 Week 0 Week 4 Week 8 Week 12 | | Ld Administration Administration After 8 weeks of administration, cholesterol and LDL-C were significan
Slide 10: Manages blood sugar (animal testing)
568-R manages blood sugar —=-r Animal Testing Insulin expression & e Methylglyoxal Rosiglitazone injection (diabetic drug) Monascin maintained insulin expression levels against methylglyoxal-induced damage to pancreatic tissues
Slide 11: Clinical trial: fasting blood glucose
<= Clinical Trial Fasting Blood Glucose 110 3 = 105 £ 100 95 90 WeekO0 Week6 Week12 Week 16 After 12 weeks of administration, fasting blood glucose was significantly reduced by 9.3%
Slide 12: ANKASCIN 568-R manages blood pressure
fh <h sslas'as's I MW “ANKASGIN" 568-R manages blood ie ‘®— Spontaneously hypertensive rats —t#— Spontaneously hypertensive rats fed with ANKASCIN 568-R Systolic blood pressure Diastolic blood pressure 5 0 o S '—® Short term E -10 “15 ss i : —— “i _— zy - =2 H 180 7 - —o Long term 2 a 0 mm ig 2 / 21
Slide 13: Aorta thin sections of hypertensive rats
The aorta thin sections of spontaneously hypertensive rats Irregular elastin fibers Elastin fibers were straighter and easier to manage blood pressure change
Slide 14: ANKASCIN 568-R supports memory
ANKASGIN-568-R supports memory . C: normal diet R: ANKASCIN 568-R A: treated with aluminum Key risk factors (AB, ,, AB, so pTau) for Alzheimer’s disease (dementia) were significantly reduced in hippocampus
Slide 15: Animal testing: APP expression
= Animal Testing Amyloid Precursor Protein (APP) expression E Treated with aluminum Control Another key risk factor (APP) for Alzheimer’s disease was significantly reduced in hippocampus
Slide 16: MMSE cognitive status clinical trial
MMSE (Mini-Mental State Examination): cognitive statuses Administration for 9 months Placebo group Testing group Change from baseline Change from baseline Month Month Clinical improvement ©
Slide 17: FDA-approved New Dietary Ingredient
FDA-approved New Dietary Ingredient Clinical Trials Toxicity Tests! 2 M1 Liver functions AST, ALT, y-GTP study (230X dosage) A Kidney functions a In vitro chromosomal Creatinine, BUN, PH in urine = | @ 90-day oral toxicity aberration assay ; d : Se. / wf Micronucleus assay ae wie Ames test
Slide 18: Active compounds and specifications
Active compounds ANKASGIN’568-R | SPECIFICATIONS Aspect Monascin 2 28 mg/g Ankaflavin 2 9 mg/g Daily dosage Powder Applicable formulation Blood lipids: 110 mg Blood sugar: 220 mg Blood pressure: 220 mg Memory & cognitive health: 220 mg Powder sachets, tablets, capsules C @\ SunWay Biotech Co., LTD.
Sunway Biotech — Investor Presentation (November 2016) on 6ix